The total market value of a company’s outstanding shares, calculated by multiplying the current share price by the total number of outstanding shares.
CN¥61.54B
EV
Enterprise Value (EV)
A comprehensive measure of a company's total value, calculated by adding market capitalization and total debt, then subtracting cash and cash equivalents. Unlike market cap, EV reflects the interests of all stakeholders, including shareholders, debt holders, and preferred equity investors, making it a key metric for valuation and financial analysis.
CN¥62.40B
Shares Outstanding
Shares Outstanding
Shares outstanding are the total number of a company’s shares currently held by all its shareholders, including institutional investors and company insiders.
1.11B
Beta
Beta (β)
A measure of a stock’s volatility relative to the overall market. A beta greater than 1 indicates higher volatility than the market, while a beta less than 1 suggests lower volatility.
-0.15
Wall Street View
Analyst Rating
Analyst Rating
Analyst ratings reflect expert opinions on a stock’s investment potential, based on in-depth research and market analysis. Ratings fall into five categories, ranging from most positive to least positive:
✅ Buy – Strongest rating; high confidence in outperformance
🔹 Outperform – Expected to beat the market
⚖️ Hold – Likely to perform in line with the market
🔻 Underperform – Expected to lag behind the market
❌ Sell – Weakest rating; suggests reducing or exiting
BUY
Analyst Target Price
Analyst Price Target
The Analyst Price Target is the average forecasted stock price over the next 12 months, based on estimates from professional financial analysts. It reflects their expectations for the stock’s future performance, considering factors like earnings growth, industry trends, and market conditions.
CN¥88.53
P/E 2025E
Forward P/E Ratio
The Forward Price-to-Earnings (P/E) Ratio measures a company’s current share price relative to its estimated earnings per share (EPS) for the current unreported year. This valuation metric provides insight into how much investors are willing to pay today for each dollar of projected earnings, offering a forward-looking perspective on the stock's potential growth and valuation.
117.21x
P/Revenue 2025E
Forward P/Revenue
The Forward P/Revenue ratio measures a company’s stock price relative to its expected revenue per share for the current year. This ratio helps investors assess how much they are paying for each dollar of revenue the company is forecasted to generate.
13.84x
Historical 3Y Growth Rate
Historical 3Y Growth Rate
This refers to the average compound annual growth rate of a company’s financial metric over the past three years (last 3Y CAGR).
Revenue
Revenue
The total income generated by a company from its core business operations, typically from the sale of goods or services, before any costs or expenses are deducted.
10.30%
EPS
Earnings Per Share (EPS)
Earnings Per Share (EPS) represents a company's net income divided by the number of outstanding shares. EPS is a key metric for evaluating a company's profitability on a per-share basis, providing insight into how much profit is generated for each share owned by investors.
3.00%
Operating Cash Flow
Operating Cash Flow (OFC)
The cash flow generated by a company’s core operations after deducting capital expenditures necessary to maintain or expand the asset base. It represents the actual cash available for discretionary use, such as paying down debt or distributing dividends.
131.10%
Free Cash Flow
Free Cash Flow (FCF)
The amount of cash a company generates after covering its operating expenses and capital expenditures. Free cash flow represents the cash available for reinvestment, debt repayment, dividends, or other corporate activities, making it a key indicator of financial flexibility and long-term sustainability.
-
Forecasted 3Y Growth Rate
Forecasted 3Y Growth Rate
This refers to the projected compound average annual growth rate of a company’s financial metric over the next three years (next 3Y CAGR). It is a forward-looking estimate that provides insight into the expected growth trajectory.
Revenue
Revenue
The total income generated by a company from its core business operations, typically from the sale of goods or services, before any costs or expenses are deducted.
20.40%
EPS
Earnings Per Share (EPS)
Earnings Per Share (EPS) represents a company's net income divided by the number of outstanding shares. EPS is a key metric for evaluating a company's profitability on a per-share basis, providing insight into how much profit is generated for each share owned by investors.
34.40%
Operating Cash Flow
Operating Cash Flow (OFC)
The cash flow generated by a company’s core operations after deducting capital expenditures necessary to maintain or expand the asset base. It represents the actual cash available for discretionary use, such as paying down debt or distributing dividends.
42.00%
Free Cash Flow
Free Cash Flow (FCF)
The amount of cash a company generates after covering its operating expenses and capital expenditures. Free cash flow represents the cash available for reinvestment, debt repayment, dividends, or other corporate activities, making it a key indicator of financial flexibility and long-term sustainability.
194.00%
Margins & Returns
Gross Margin 2025E
Gross Margin
Gross margin represents the percentage of revenue a company retains after accounting for the direct costs of producing its goods or services, also known as cost of goods sold (COGS). It’s calculated by subtracting COGS from revenue and then dividing by Revenue.
74.90%
Net Profit Margin 2025E
Net Profit Margin
Net profit margin measures the percentage of a company’s revenue that remains as profit after all expenses are deducted. It’s calculated by dividing net income by total revenue.
11.90%
ROE 2025E
Return on Equity (ROE)
ROE measures how effectively a company uses its shareholders’ equity to generate profit. It’s calculated by dividing net income by shareholders’ equity, giving an indication of how efficiently the company is generating returns on the investments made by its shareholders.
12.50%
ROCE 2024
Return on Common Equity (ROCE)
A financial ratio that measures a company’s profitability in relation to common shareholders’ equity. ROCE is calculated by dividing net income available to common shareholders by average common equity. It indicates how effectively management is using shareholders' funds to generate profits.
9.42%
Dividends
DPS 2025E
Dividends Per Share (Dividend / Share)
The total dividends paid by a company divided by the number of outstanding shares. DPS represents the amount of earnings distributed to shareholders and is a key metric for evaluating a company’s payout policy.
CN¥0.07
Payout Ratio 2025E
Payout Ratio
The percentage of a company’s earnings paid out to shareholders as dividends. It is calculated by dividing total dividends by net income and is used to assess how much of a company’s profit is being returned to investors.
14.89%
Div. Yield 2025E
Dividend Yield (Div. Yield)
Dividend yield is a financial ratio that shows how much a company pays out in dividends each year relative to its stock price. This ratio gives investors an idea of the income they can expect to receive from dividends relative to their investment.
0.13%
DPS Last 3Y CAGR
Dividends Per Share (DPS) Last 3Y CAGR
The Compound Annual Growth Rate (CAGR) of a company’s dividends per share over the last three years. This metric shows how consistently and at what rate a company has increased its dividend payouts, offering insight into its dividend growth history and reliability.
30.90%
Price Dynamic
Price
%
1M
3M
6M
1Y
3Y
5Y
Peers
Peers
Peers refer to companies within the same industry or sector that are similar in size, business model, or market position. Comparing a company’s performance to its peers helps investors assess how well the company is doing relative to others in its field.
About Haisco Pharmaceutical Group Co., Ltd.
Haisco Pharmaceutical Group Co., Ltd.
002653
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offers its products for anesthesia, analgesia, chronic metabolic, respiratory, autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine an...
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products in China. The company offers anesthetic analgesic, neuropsychiatric system, and digestive liver and parenteral nutrition medications; drugs for the endocrine and cardiovascular system; oncology-related drugs; andrology drugs; desonide and liprocaine cream; propofol medium/long chain fat emulsion and hydroxyethyl starch sodium chloride injection; sodium fusidicate ointment; lupatadine fumarate tablets; and caspofungin acetate and methylprednisolone sodium succinate for injection. It also develops Sisuning for sedation and anesthesia during surgery/procedure for non-endotracheal intubation, general anesthesia induction and maintenance, sedation in mechanical ventilation during intensive care, pediatric indications, and general anesthesia induction; Simenine for diabetic peripheral neuralgia, postherpetic neuralgia, and central nervous system analgesia; Beichangping for type 2 diabetes; Sysojing for postoperative analgesia of abdominal surgery, chronic kidney disease itching, orthopedic analgesia, and postoperative nausea and vomiting; HSK31858 for non-cystic fibrosis bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, and expectorant; HSK31679 for nonalcoholic steatohepatitis; HSK39297 for PHN of hemolytic disease and primary or secondary glomerular disease; HSK39775 and HSK42360 for advanced solid tumors; HSK39004 and HL231 for chronic obstructive pulmonary disease; HSK44459 for interstitial lung disease; HSK46575 for prostate cancer; and HSK41959 for advanced solid tumors. It offers its products for anesthesia, analgesia, chronic metabolic, respiratory, autoimmune diseases, etc. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2005 and is based in Shannan, China.
Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach. Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
